Flexion Therapeutics: Fighting Through COVID-19 Headwinds
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Börse:
9,850€
0,51%
Echtzeit-Aktienkurs Flexion Therapeutics Inc.
Bid:
9,600€
Ask:
10,100€
Nachrichten zur Flexion Therapeutics Inc. Aktie
Flexion Therapeutics Inc: 8-K Report
8-K...…
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net…
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…
Flexion Therapeutics Inc: 8-K Report
8-K...…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do…
Flexion Therapeutics EPS beats by $0.01, beats on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report…
Flexion Therapeutics (FLXN) Presents Q3 Commercial Metrics - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics rallies on ZILRETTA net sales
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics Inc: 8-K Report
8-K...…
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics Inc: 8-K Report
8-K...…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…
Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do…
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report…
Flexion Therapeutics: An Orthopedic Surgeon And Zilretta User Says Short The Stock
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know
Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Lets find out....…
Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock?
Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately....…
Flexion Therapeutics Inc: 8-K Report
8-K...…
Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock?
Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
BURLINGTON, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion (FLXN) Soars: Stock Adds 6.6% in Session
Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge…
Flexion +2.4% as Guggenheim sees 106% upside
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion +2.4% as Guggnheim sees 106% upside
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Planning For A Rebound In Flexion Therapeutics
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Flexion Therapeutics Is Tumbling 10% Today
The company priced a share offering, diluting existing shareholders....…
Flexion under pressure after pricing equity offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an…
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
BURLINGTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced…
How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry
Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry…
Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript
FLXN earnings call for the period ending March 31, 2020....…
Flexion Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics EPS beats by $0.06, beats on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
BURLINGTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data…
Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
BURLINGTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report…
Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain
BURLINGTON, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced new positive preclinical efficacy…
Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D.,…
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…